Organizational and Management Impact Analysis of Using the New Subcutaneous Formulation of Tocilizumab in Selected Italian Rheumatology Centers

Value Health. 2014 Nov;17(7):A383. doi: 10.1016/j.jval.2014.08.2632. Epub 2014 Oct 26.

Authors

S Ravera¹, R Tomic¹, S Adami², O Viapiana², D Paolini¹, L Bianchino¹, M Canciani³, M Farina³, G Ciancio⁴, M Govoni⁴

Affiliations

¹ Roche S. p. A., Monza, Italy.
² University of Verona, Verona, Italy.
³ Emmeffe S. r. l., Milano, Italy.
⁴ Ferrara University, Ferrara, Italy.

PMID: 27200857
DOI: 10.1016/j.jval.2014.08.2632

No abstract available